Skip to main content
TipRanks
Go Ultimate75% OFF

Croda International (50GP) AI Stock Analysis

0 Followers
GB:50GP

Croda International

(LSE:50GP)

Select Model
Rating:57Neutral
Price Target:GBX 80.00â–²(7.02% Upside)
Action:reiterated
Date:10/29/26

The overall score of 57 reflects a company with strong operational execution and cash generation, offset by significant valuation and technical headwinds. The most impactful positive factor is the solid financial foundation and confident earnings call, highlighting growth in key segments and margin expansion. However, the stock's extremely high P/E ratio and overbought technical signals present substantial risks, heavily weighing down the score. The mixed financial performance, with margin pressure on the income statement, further contributes to a cautious outlook.

Positive Factors
Innovation-led Consumer Care growthStrong growth in Beauty Actives and broader Consumer Care indicates Croda is benefiting from differentiated ingredients embedded in customer innovation. Product adoption and brand launches can support recurring demand, premium positioning, and durable expansion in attractive consumer categories.
Negative Factors
Weaker multi-year net income trendThe continued decline in bottom-line profit shows that revenue recovery has not yet restored prior earnings power. If this pattern persists, it could constrain internal reinvestment, reduce returns on capital, and make future growth more dependent on margin recovery.

Croda International (50GP) vs. iShares MSCI United Kingdom ETF (EWC)

0%5%10%15%20%25%GB:50GP+3.49%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 49.46M
Dividend Yield
789.30%
Average Volume (3M)
25.50K
Price to Earnings (P/E)
67.8
Beta (1Y)
0.08
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
5,954
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Croda International Business Overview & Revenue Model

Company Description

Croda International Plc, established in 1925 and headquartered in Goole, United Kingdom, is a global leader in the development, manufacture, and supply of high-performance specialty chemicals. The company serves a diverse international client base ac...

How the Company Makes Money

Croda makes money primarily by selling specialty chemical ingredients and ingredient technologies to business customers (B2B) across consumer care and industrial markets. Its revenue model is largely product sales, where customers pay per unit/volume...

Croda International Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:-11.01%|Next Earnings Date:Jul 25, 2018
Earnings Call SentimentPositive

The call conveyed a broadly positive performance: underlying sales, EPS and margins improved with clear signs of momentum in innovation-led growth (notably Beauty Actives and Pharma Ingredients), transformation savings are materializing, and strategic capacity expansions in Asia support future growth. Challenges remain—Pharma Solutions timing, Crop Protection weakness, regional/segment softness (North America mass market), working capital outflows and one-off OpEx inflation—but these are presented as manageable or phased rather than structural. Management reiterated full-year guidance (organic sales growth 3–6%) and the 3-year targets through 2028, signaling confidence in execution.

Positive Updates

Group Sales Growth
Constant currency sales up 5% to GBP 881 million in H1 2026, with volumes +1% and price/mix +4%.

Negative Updates

Pharma Solutions Underperformance and Phasing
Pharma Solutions was below expectations in H1 due to project phasing; business is lumpy and revenue recognition timing may cause H2 dependency on order book to deliver improvement.

Company Guidance

Management reiterated unchanged full‑year guidance, forecasting organic sales growth of 3–6% and a further increase in adjusted operating margin, with adjusted operating profit expectations unchanged and FX sensitivities provided; they also said the Q2 exit rate gives confidence in sequential margin improvement in H2 and that the group remains on track for its 3‑year/2028 financial framework. In support, H1 sales were £881m (+5%) with NPP +7%, volumes +1% and price/mix +4%; adjusted operating profit was £156m (+7%) and margin rose to 17.7% (from 17.2%), EPS 78p (+9%), EBITDA £208m, free cash flow £38m (vs £28m), net debt £578m (leverage 1.4x) and an interim dividend of 48p. Management said transformation delivered £18m of H1 savings (cumulative £46m toward a £100m target), CapEx fell to £43m, and a working‑capital program aims for ~£50m of structural savings by 2028 to offset typical annual WC funding of £20–30m.

Croda International Financial Statement Overview

Summary

Financial performance is mixed but resilient. Cash flow generation is a key strength, with robust operating cash flow and a 25% improvement in free cash flow. The balance sheet is solid with low leverage (0.35 debt-to-equity). However, the income statement shows significant gross margin contraction to 35.8% and a sharp drop in net income, which tempers the overall score.

Income Statement

55Neutral

Balance Sheet

75Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.72B1.70B1.63B1.69B2.09B1.89B
Gross Profit615.90M608.70M733.90M730.00M864.90M825.60M
EBITDA390.10M380.70M374.50M388.50M924.80M549.40M
Net Income79.50M62.00M158.50M171.00M649.30M320.80M
Balance Sheet
Total Assets3.53B3.41B3.51B3.58B3.61B3.29B
Cash, Cash Equivalents and Short-Term Investments205.30M172.80M166.80M172.50M320.60M112.80M
Total Debt783.20M696.60M699.10M710.10M615.80M936.00M
Total Liabilities1.34B1.21B1.21B1.21B1.18B1.53B
Stockholders Equity2.17B2.19B2.28B2.35B2.42B1.75B
Cash Flow
Free Cash Flow187.80M171.80M137.60M156.80M160.90M190.50M
Operating Cash Flow283.40M289.50M319.40M337.50M313.30M349.20M
Investing Cash Flow-93.00M-109.80M-139.10M-409.80M418.10M-218.40M
Financing Cash Flow-175.90M-152.60M-182.60M-52.40M-550.90M-111.90M

Croda International Technical Analysis

Technical Analysis SentimentNegative
Last Price74.75

Price Trends

50DMA75.86Negative
100DMA77.95Negative
200DMA78.14Negative

Market Momentum

MACD-0.49Positive
RSI15.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:50GP, the sentiment is Negative. The current price of 74.75 is below the 20-day moving average (MA) of 75.88, below the 50-day MA of 75.86, and below the 200-day MA of 78.14, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 15.42 is Positive, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:50GP.

Croda International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

GB:50GP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
GB:SYNTGB:SYNT60NeutralGBP 185.26M-1.40-13.27%―-4.98%-43.98%
GB:VCTGB:VCT59NeutralGBP 795.31M-37.43-4.95%3.12%-1.24%-166.15%
GB:50GPGB:50GP57NeutralGBP 5.42B67.753.65%789.30%――
GB:JMATGB:JMAT56NeutralGBP 2.90B-33.30-6.76%4.53%26.60%14.94%
GB:ELMGB:ELM53NeutralGBP 1.06B18.8711.29%1.78%-11.73%―

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%GB:50GPGB:ELMGB:JMATGB:SYNTGB:VCTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:50GP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:50GPCroda International (50GP)74.752.523.49%
GB:ELMElementis plc186.8034.2522.45%
GB:JMATJohnson Matthey (Uk)2364.00417.6321.46%
GB:SYNTSynthomer plc102.6052.95106.65%
GB:VCTVictrex plc861.00310.2856.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026